Atlas Trials

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Clinical trial NCT02251548 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02251548
Sponsor
Dana-Farber Cancer Institute
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Chronic Lymphocytic LeukemiaLeukemia
Start date
2014-10-01
Primary completion
2025-01-01
Enrollment
85

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.